Literature DB >> 22433769

Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans.

Ya-Chen Tina Shih1, John F Ward, Curtis A Pettaway, Ying Xu, Surena F Matin, John W Davis, Benjamin P Thompson, Linda S Elting.   

Abstract

BACKGROUND: Costs and benefits of emerging prostate cancer treatments for young men (age < 65 years) in the United States are not well understood. We compared utilization, clinical outcomes, and costs between two types of radical prostatectomy (RP)--minimally invasive prostatectomy (MIRP) and retropubic prostatectomy (RRP)--among young patients.
METHODS: We extracted from LifeLink Health Plan Claims Database, a commercial claims database, information on 10,669 patients receiving either MIRP or RRP between 2003 and 2007. In unadjusted analyses, we used chi-square tests to compare clinical outcomes and nonparametric bootstrapping method to compare costs between the MIRP and RRP groups. We applied logistic, Cox proportional hazard, and extended estimation equation methods to examine the association between surgical modality and perioperative complications, anastomotic stricture, and costs while controlling for age, comorbidity, and health plan characteristics.
RESULTS: The percentage of prostatectomies performed as MIRP increased from 5.7% in 2003 to 50.3% in 2007. Patients with more comorbidity were more likely to undergo RRP than MIRP. Compared with the RRP group, the MIRP group had a significantly lower rate of perioperative complications (23.0% vs. 30.4%; P < 0.001) and a lesser tendency for anastomotic strictures (hazard ratio 0.42; 95% CI 0.35-0.50) within the first postoperative year but had higher hospitalization costs ($19,998 vs. $18,424; P < 0.001) despite shorter hospitalizations (1.7 days vs. 3.1 days; P < 0.001). Similar findings were reported in the subgroup analysis of patients with comorbidity score 0.
CONCLUSION: MIRP among nonelderly patients increased substantially over time. MIRP was found to have fewer complications. Lower costs of complications appeared to have offset higher hospitalization costs of MIRP. Copyright Â
© 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22433769     DOI: 10.1016/j.jval.2011.10.008

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  4 in total

1.  Learning curve assessment of robot-assisted radical prostatectomy compared with open-surgery controls from the premier perspective database.

Authors:  John W Davis; Usha S Kreaden; Jessica Gabbert; Raju Thomas
Journal:  J Endourol       Date:  2014-02-06       Impact factor: 2.942

2.  Delivering high-quality and affordable care throughout the cancer care continuum.

Authors:  Ya-Chen Tina Shih; Patricia A Ganz; Denise Aberle; Amy Abernethy; Justin Bekelman; Otis Brawley; James S Goodwin; Jim C Hu; Deborah Schrag; Jennifer S Temel; Lowell Schnipper
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

3.  Cost-effectiveness analysis of robotic-assisted versus retropubic radical prostatectomy: a single cancer center experience.

Authors:  Renato Almeida Rosa de Oliveira; Gustavo Cardoso Guimarães; Thiago Camelo Mourão; Ricardo de Lima Favaretto; Thiago Borges Marques Santana; Ademar Lopes; Stenio de Cassio Zequi
Journal:  J Robot Surg       Date:  2021-01-08

Review 4.  Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.

Authors:  Florian Rudolf Schroeck; Bruce L Jacobs; Sam B Bhayani; Paul L Nguyen; David Penson; Jim Hu
Journal:  Eur Urol       Date:  2017-03-31       Impact factor: 20.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.